<DOC>
	<DOCNO>NCT01666327</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics pharmacodynamics single oral dose MT-1303 subject inflammatory bowel disease .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Pharmacodynamics Study MT-1303 Subjects With Inflammatory Bowel Disease</brief_title>
	<detailed_description>This open-label , non-randomised , single-dose study evaluate safety , tolerability , pharmacokinetics pharmacodynamics MT-1303 subject inflammatory bowel disease ( Crohn 's Disease Ulcerative Colitis ) .</detailed_description>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<criteria>A body mass index ( BMI ) range 16 34 kg/m2 Subjects diagnose Crohn 's Disease Ulcerative Colitis least 6 month prior Screening , clinically confirm either radiological , endoscopic histological examination . Subjects least one flare within 18 month prior Screening . Confirmed medical record inflammatory lesion intestinal tract Present past history clinically significant gastrointestinal surgery . Present past history clinically significant stenosis , stricture fistula small intestine colon . Known hypersensitivity formulation excipients .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Crohn 's Disease</keyword>
	<keyword>Ulcerative Colitis</keyword>
</DOC>